These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38280539)

  • 1. Lipid mediators in glaucoma: Unraveling their diverse roles and untapped therapeutic potential.
    Mathew DJ; Sivak JM
    Prostaglandins Other Lipid Mediat; 2024 Apr; 171():106815. PubMed ID: 38280539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specialized Pro-Resolving Mediators in Neuroinflammation: Overview of Studies and Perspectives of Clinical Applications.
    Valente M; Dentoni M; Bellizzi F; Kuris F; Gigli GL
    Molecules; 2022 Jul; 27(15):. PubMed ID: 35956787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators.
    Perez-Hernandez J; Chiurchiù V; Perruche S; You S
    Front Immunol; 2021; 12():768133. PubMed ID: 34868025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma.
    Kytikova O; Novgorodtseva T; Denisenko Y; Antonyuk M; Gvozdenko T
    Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31216723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specialized Pro-Resolving Lipid Mediators: New Therapeutic Approaches for Vascular Remodeling.
    Díaz Del Campo LS; Rodrigues-Díez R; Salaices M; Briones AM; García-Redondo AB
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Clinical Applications of Pro-Resolving Lipids Mediators from Docosahexaenoic Acid.
    Beyer MP; Videla LA; Farías C; Valenzuela R
    Nutrients; 2023 Jul; 15(15):. PubMed ID: 37571256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel mediators and mechanisms in the resolution of infectious inflammation: evidence for vagus regulation.
    Serhan CN; de la Rosa X; Jouvene C
    J Intern Med; 2019 Sep; 286(3):240-258. PubMed ID: 30565762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive Immunity: New Aspects of Pathogenesis Underlying Neurodegeneration in Glaucoma and Optic Neuropathy.
    Jiang S; Kametani M; Chen DF
    Front Immunol; 2020; 11():65. PubMed ID: 32117239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection in glaucoma: Mechanisms beyond intraocular pressure lowering.
    Tribble JR; Hui F; Quintero H; El Hajji S; Bell K; Di Polo A; Williams PA
    Mol Aspects Med; 2023 Aug; 92():101193. PubMed ID: 37331129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of the endothelin A (ET
    McGrady NR; Minton AZ; Stankowska DL; He S; Jefferies HB; Krishnamoorthy RR
    BMC Neurosci; 2017 Mar; 18(1):27. PubMed ID: 28249604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inducible rodent glaucoma model that exhibits gradual sustained increase in intraocular pressure with distinct inner retina and optic nerve inflammation.
    Mathew DJ; Livne-Bar I; Sivak JM
    Sci Rep; 2021 Nov; 11(1):22880. PubMed ID: 34819548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical administration of rapamycin promotes retinal ganglion cell survival and reduces intraocular pressure in a rat glaucoma model.
    Wang F; Ma F; Song Y; Li N; Li X; Pang Y; Hu P; Shao A; Deng C; Zhang X
    Eur J Pharmacol; 2020 Oct; 884():173369. PubMed ID: 32712092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DRP1 inhibition rescues retinal ganglion cells and their axons by preserving mitochondrial integrity in a mouse model of glaucoma.
    Kim KY; Perkins GA; Shim MS; Bushong E; Alcasid N; Ju S; Ellisman MH; Weinreb RN; Ju WK
    Cell Death Dis; 2015 Aug; 6(8):e1839. PubMed ID: 26247724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Pharmacology of Inflammation Resolution in Atherosclerosis.
    Kotlyarov S; Kotlyarova A
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators.
    Yasmeen N; Selvaraj H; Lakhawat SS; Datta M; Sharma PK; Jain A; Khanna R; Srinivasan J; Kumar V
    Biochem Pharmacol; 2023 Mar; 209():115437. PubMed ID: 36731803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of glaucoma: focus on pharmacological therapy.
    Marquis RE; Whitson JT
    Drugs Aging; 2005; 22(1):1-21. PubMed ID: 15663346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of potential novel glaucoma therapeutic options independent of intraocular pressure.
    Shalaby WS; Ahmed OM; Waisbourd M; Katz LJ
    Surv Ophthalmol; 2022; 67(4):1062-1080. PubMed ID: 34890600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural resolution of inflammation.
    Freire MO; Van Dyke TE
    Periodontol 2000; 2013 Oct; 63(1):149-64. PubMed ID: 23931059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resolvins, Protectins, and Maresins: DHA-Derived Specialized Pro-Resolving Mediators, Biosynthetic Pathways, Synthetic Approaches, and Their Role in Inflammation.
    Ferreira I; Falcato F; Bandarra N; Rauter AP
    Molecules; 2022 Mar; 27(5):. PubMed ID: 35268778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targets of Neuroprotection in Glaucoma.
    He S; Stankowska DL; Ellis DZ; Krishnamoorthy RR; Yorio T
    J Ocul Pharmacol Ther; 2018; 34(1-2):85-106. PubMed ID: 28820649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.